BASKING RIDGE, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter and nine-months ended September 30, 2019 after the close of the market on Wednesday, November 13, 2019.  Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.For more information, visit www.electrocore.com.Investors:
Hans Vitzthum
LifeSci Advisors
(+1) 617-535-7743
[email protected]orMedia Contact:
Sara Zelkovic
LifeSci Public Relations
(+1) 646-876-4933
[email protected]
Bay Street News